Download - CPG Urogynecology
-
8/9/2019 CPG Urogynecology
1/71
Philippine Obstetrical and
Gynecological Society (POGS), Foundation, Inc.
November 2010
Task Force on Clinical Practice Guidelines
on Urogynecology
CLINIC L PR CTICE GUIDELINES
on
UROGYNECOLOGY
"#$%& '()%
-
8/9/2019 CPG Urogynecology
2/71
REGTA L. PICHAY, MD
PresidentPhilippine Obstetrical and Gynecological Society (Foundation), Inc. (POGS), 2010
REGTA L. PICHAY, MD
FOREWORD
-
8/9/2019 CPG Urogynecology
3/71
EFREN J. DOMINGO, MD, PhD
Editor in Chief, Clinical Practice Guidelines, 2010
The Clinical Practice Guidelines on Urogynecology is the First Edition of this
Publication, 2010. The Philippine Obstetrical and Gynecological Society,
(Foundation), Inc. (POGS), through the Committee on Clinical Practice Guidelines
initiated and led to completion the publication of this manual in plenary consultation
with the Residency Accredited Training Hospitals’ Chairs and Training Officers, The
Regional Board of Directors, The Board of Trustees, The Task Force on
Urogynecology and the Committee on Continuing Medical Education (CME).
This publication represents the collective effort of the POGS in updating the
clinical practice of Obstetrics and Gynecology, specifically on Urogynecology, andmaking it responsive to the most current and acceptable standard in this procedure.
A greater part of the inputs incorporated in this edition are the contributions
originating from the day-to-day academic interactions from the faculty of the different
Residency-Accredited Hospitals in Obstetrics and Gynecology in the country.
This Clinical Practice Guideline on Urogynecology is envisioned to become
the handy companion of the Obstetrician-Gynecologist in his/her day-to-day rendition
of quality care and decision making in managing the Gynecologic patient. This is also
envisioned to provide the academic institutions in the country and in Southeast Asia
updated information on Urogynecology as being practiced in the Philippines.
Profound gratitude is extended to all the members of the POGS, the Chairs
and Training Officers of the Residency-Training Accredited Institutions, the Regional
Directors, The Task Force Reviewers/Contributors, The CME Committee members,
and the 2010 POGS Board of Trustees.
EFREN J. DOMINGO, MD, PhD
INTRODUCTION
-
8/9/2019 CPG Urogynecology
4/71
BOARD OF TRUSTEES 2010
OFFICERS
Regta L. Pichay, MD
President
Sylvia delas Alas Carnero, MD
Vice President
Ditas Cristina D. Decena, MDSecretary
Jericho Thaddeus P. Luna, MD
Treasurer
Gil S. Gonzales, MD
Public Relations Officer
BOARD OF TRUSTEES
Efren J. Domingo, MD, PhD
Virgilio B. Castro, MD
Blanca C. de Guia, MD
Raul M. Quillamor, MD
Rey H. delos Reyes, MD
Ma. Cynthia Fernandez-Tan, MD
-
8/9/2019 CPG Urogynecology
5/71
COMMITTEE ON CLINICAL PRACTICE GUIDELINES ON
UROGYNECOLOGY
Efren J. Domingo, MD, PhD
Editor in Chief
MEMBERSAnn Marie C. Trinidad, MD Ma. Victoria V. Torres, MD
Lisa T. Prodigalidad-Jabson, MD Christine D. Dizon, MD
Rommel Z. Duenas, MD
MANAGING EDITOR
Ana Victoria V. Dy Echo, MD
TECHNICAL STAFF ASSISTANTS
Ms. Emiliana C. Enriquez
Ms. Jhasmin G. De Guzman
TASK FORCE ON UROLOGYNECOLOGY
Lisa T. Prodigalidad-Jabson, MD
Chair
Members
Almira J. Amin-Ong, MD Lennette L. Chan, MD
Jennifer B. Jose, MD Maria Teresa C. Luna, MD
Manuel S. Ocampo, MD Judith M. Sison, MD
TASK FORCE REVIEWERS AND PLENARY REVIEWERS
Rainerio S. Abad, MD Ma. Flores Adiong, MD Imelda O. Andres, MDRuth Jinky Aposaga, MD Prudence V. Aquino, MD Nurlinda Arumpac, MD
Ricardo Braganza, MD Sybil Lizanne R. Bravo, MD Maria Nelvez Candilario, MD
Grace D. Caras, MD Abigail Elsie D. Castro, MD Ma. Theresa Cedullo, MD Ma.
Cherrie Climaco, MD Antonio Cortez, MD Lara David-Bustamante, MD
Macrina A. De Guzman, MD Grace D. delos Angeles, MD Lorina Q. Esteban, MD
Rodante P. Galiza, MD Gil S. Gonzales, MD Maribel Hidalgo-Co, MD
May N. Hipolito, MD Rosemarie R. Hudencial, MD Humildada Asumpta Igana, MD
Margarette Lavalle, MD Lourdes Ledesma, MD Jericho Thaddeus P. Luna, MD
Ma. Cecilia Maclang, MD Marilou Mangubat, MD Corazon B. Mata, MD
Jocelyn Z. Mariano, MD Rudie Frederick B. Mendiola, MD Marites Mendoza, MD
Suzette Miclat, MD Cristia S. Padolina, MD Mary Christine F. Palma, MD
Belen Pantangco-Rajagukguk, MD Gladys Pelicano, MD Regta L. Pichay, MD
Sarah Pingol, MD Kenet Prado, MD Ma. Carmen H. Quevedo, MD
Rico E. Reyes, MD Ricalynn Rivera, MD Bella G. Rodriguez, MD
Pura Rodriguez-Caisip, MD Alice Salvador, MD Jean Marie Salvador, MD
Esmarliza Tacud-Luzon, MD Patricia L. Tan, MD Ma. Theresa B. Tenorio, MD
Jean Anne B. Toral, MD Florentina A. Villanueva, MD Julieta Villanueva, MD
Faith Villaruiz, MD Marilou Viray, MD Regina P. Vitriolo, MD
Amaryllis Digna A. Yazon, MD
Regional Directors
Betha Fe M. Castillo, MD (Region 1) Noel C. de Leon, MD (Region 2)
Concepcion P. Argonza, MD (Region 3) Ernesto S. Naval, MD (Region 4)
Diosdado V. Mariano, MD (Region 4A NCR) Cecilia Valdes-Neptuno, MD (Region 5)
Evelyn R. Lacson, MD (Region 6) Belinda N. Pañares, MD (Region 7)
Fe G. Merin, MD (Region 8) Cynthia A. Dionio, MD (Region 9) Jana Joy R. Tusalem, MD (Region 10) Amelia A. Vega, MD (Region 11)
-
8/9/2019 CPG Urogynecology
6/71
DISCLAIMER, RELEASE AND WAIVER OF RESPONSIBILITY
• This is the Clinical Practice Guidelines (CPG) on Urogynecology, First Edition,
November 2010.• This is the publication of the Philippine Obstetrical and Gynecological Society,
(Foundation), Inc. (POGS).
• This is the ownership of the POGS, its officers, and its entire membership.• The obstetrician gynecologist, the general practitioner, the patient, the student, the
allied medical practitioner, or for that matter, any capacity of the person orindividual who may read, quote, cite, refer to, or acknowledge, any, or part, or the
entirety of any topic, subject matter, diagnostic condition or idea/s willfullyrelease and waive all the liabilities and responsibilities of the POGS, its officers
and general membership, as well as the Committee on the Clinical PracticeGuidelines and its Editorial Staff in any or all clinical or other disputes,
disagreements, conference audits/controversies, case discussions/critiquing.• The reader is encouraged to deal with each clinical case as a distinct and unique
clinical condition, which will never fit into an exact location if reference is made
into any or all part/s of this CPG.
• The intention and objective of this CPG is to serve as a guide, to clarify, to makeclear the distinction. It is not the intention or objective of this CPG to serve as the
exact and precise answer, solution and treatment for clinical conditions and
situations. It is always encouraged to refer to the individual clinical case as the
one and only answer to the case in question, not this CPG.
• It is hoped that with the CPG at hand, the clinician will find a handy guide thatleads to the a clue, to a valuable pathway that leads to the discovery of clinical
tests leading to clinical treatments and eventually recovery.• In behalf of the POGS, its Board of Trustees, the Committee on The Clinical
Practice Guidelines, 2010, this CPG is meant to make each one of us a perfect
image of Christ, the Healer.
-
8/9/2019 CPG Urogynecology
7/71
Introduction ……………………………………………………………… 1
Dr. Lisa T. Prodigalidad-Jabson
Definition of Terms (Standardization of Terminology) …………………
Dr. Almira J. Amin-Ong
Evaluation of Pelvic Floor Dysfunction and POP-Q Scoring System …..
Dr. Judith M. Sison
Conservative Management of Stress Urinary Incontinence ………………
Dr. Almira J. Amin-Ong
Surgical Management of Stress Urinary Incontinence …………………….
Dr. Lisa T. Prodigalidad-Jabson
Conservative Management of Pelvic Organ Prolapse ……………………
Dr. Maria Teresa C. Luna
Surgical Management of Pelvic Organ Prolapse …………………………
Dr. Manuel S. Ocampo, Jr and Dr. Lisa T. Prodigalidad-Jabson
Fecal Incontinence and Obstetric Anal Sphincter Injuries (OASIS) ……..
Dr. Lennette L. Chan
Urinary Retention ………………………………………………………...
Dr. Jennifer B. Jose
Appendix: Level of Evidence and Grade of Recommendations ………….
CPG ON UROGYNECOLOGY
TOPICS / CONTENTS / AUTHOR/S
-
8/9/2019 CPG Urogynecology
8/71
INTRODUCTIONLisa T. Prodigalidad-Jabson, MD
Urogynecology and Reconstructive Pelvic Surgery has long been a recognized
specialty in the field of Obstetrics and Gynecology. However, here in the Philippines,Urogynecology is still at its infancy stage and only recently has there been a growing
interest in this field of pelvic reconstruction. Pelvic floor disorders such as pelvic
organ prolapse (POP), fecal incontinence (FI), and urinary incontinence (UI) are, at
present, aspects of women’s health that are frequently neglected or ignored.
POP is among the most common indications for benign gynecologic surgery.
A review by the National Center for Health Statistics in the United States lists genital
prolapse as one of the 3 most common reasons for hysterectomy in women. In the
University of the Philippines - Philippine General Hospital alone, over 100 cases of
vaginal hysterectomies are performed each year for prolapse. In a recent review by
the Women’s Health Initiative, POP was found to be a very common condition in
women during menopause and was consistently related to parity.2 This becomes of particular importance in a society such as ours where family planning, althoughstrongly advocated, is not widely practiced.
Likewise, female UI is a common problem that is often unrecognised, neglected,or ignored. It is a condition believed to be as natural as pregnancy, childbirth,
menopause, and aging. The prevalence of UI is reported to range from 2% to 57% andafflicts both the young and old. The wide range may reflect the difficulty in
estimating the incidence of UI, as most women experiencing such symptoms often do
not seek medical advice. In a 2001 study by the Asia-Pacific Continence Advisory
Board, the prevalence of overactive bladder as a cause of incontinence in Asians was
noted to be 51.4%. More specifically, Diokno states a 13% prevalence rate of UI
among Filipinos.3 This is in contrast to the incidence of 31% reported by Ramoso-
Jalbuena in 1994.4
With recent emphasis on women’s health and quality of life, caring for women
with various pelvic floor disorders would become an increasingly important aspect of
women’s health care. And, for a rapidly growing and aging population, the demand
for such care will inevitably escalate.
References
1. Milsom I, Altman D, Lapitan MC, Nelson R, Sillen U, and Thom D. Epidemiology of urinary(UI) and fecal incontinence (FI) and pelvic organ prolapse (POP). In Abrams P, Cardozo L,Khoury S, and Wein A (Eds). Incontinence: WHO–ICUD International Consultation on
Incontinence, 4th
edition, 2009.
2. Hendrix SL, Clark A, Nygaard I, Aragaki A, Barnabei V, McTiernan A. Pelvic organ prolapsein the women’s health initiative: gravity and gravidity. Am J Obstet Gynecol
2002;186(6):1160-6.
3. Lapitan MC and Chye PLH on behalf of the Asia-Pacific Continence Advisory Board. Theepidemiology of overactive bladder among females in Asia: A questionnaire survey. Int
Urogyn J 2001;12(4):226-31.
4. Ramoso-Jalbuena J. Climacteric filipino women: a preliminary survey in the Philippines. Maturitas 2004;19(3):183-190.
-
8/9/2019 CPG Urogynecology
9/71
DEFINITION OF TERMS Almira J. Amin-Ong, MD
Lower urinary tract symptoms are classified into three major categories
namely, storage, voiding and postmicturition symptoms. The following terms areculled from the latest International Continence Society (ICS) Standardization ofTerminology for lower urinary tract symptoms published in 2009. The terminologies
serve to eliminate confusion and facilitate communication amongst clinicians.
I. SYMPTOMS SUGGESTIVE OF LOWER URINARY TRACT
DYSFUNCTION
A. STORAGE SYMPTOMS
1. Urgency – the complaint of a sudden compelling desire to pass urine which isdifficult to defer
2. Increased daytime frequency – the complaint of the patient who considers thatshe voids too often by day; equivalent to pollakisuria used in many countries
3. Nocturia – the complaint that the individual has to wake up at night one ormore times to void
4. Stress urinary incontinence (SUI) – the complaint of involuntary leakage oneffort or exertion, or on sneezing or coughing
5. Urge UI – the complaint of involuntary leakage accompanied by orimmediately preceded by urgency
6. Mixed UI – the complaint of involuntary leakage associated with urgency andalso with exertion, effort, sneezing or coughing
7. Nocturnal enuresis – complaint of loss of urine occurring during sleep8. Continuous urinary leakage – the complaint of continuous leakage9. Normal bladder sensation – the individual is aware of bladder filling and
increasing sensation up to a strong desire to void
10. Increased bladder sensation – the individual feels an early and persistentdesire to void
11. Reduced bladder sensation – the individual is aware of bladder filling but doesnot feel a definite desire to void
12. Absent bladder sensation – the individual reports no sensation of bladder
filling or desire to void13. Non-specific bladder sensation – the individual reports no specific bladdersensation but may perceive bladder filling as abdominal fullness, vegetative
symptoms, or spasticity
B. VOIDING SYMPTOMS
1. Slow stream – perception of the individual of reduced urine flow, usuallycompared to previous performance or in comparison with others
2. Splitting or spraying – self-explanatory3. Intermittent stream (intermittency) – urine flow described as a stop and start
flow, on one or more occasions, during micturition4. Hesitancy – difficulty in initiating micturition resulting in a delay in the onset
-
8/9/2019 CPG Urogynecology
10/71
of voiding after the individual is ready to pass urine
5. Straining – describes the muscular effort used to either initiate, maintain orimprove the urinary stream
6. Terminal dribble – term used when an individual describes a prolonged final part of micturition, when the flow has slowed to a trickle/dribble
C. POSTMICTURITION SYMPTOMS
1. Feeling of incomplete emptying – self-explanatory term for a feelingexperienced by the individual after passing urine
2. Postmicturition dribble – involuntary loss of urine immediately after the patient has passed urine, or after rising from the toilet
D. GENITAL AND LOWER URINARY TRACT PAIN
1. Bladder pain – pain felt suprapubically or retropubically, and usually
increases with bladder filling, it may persist after voiding2. Urethral pain – felt in the urethra and the individual indicates the urethra as
the site3. Vaginal pain – felt internally, above the introitus4. Perineal pain – felt between the posterior fourchette and the anus5. Pelvic pain – less well defined than the bladder, urethral or perineal pain and
is less clearly related to the micturition cycle or to bowel function and is notlocalized to any single pelvic organ
E. GENITO-URINARY PAIN SYNDROMES
1. Painful bladder syndrome – complaint of suprapubic pain related to bladderfilling accompanied by other symptoms such as increased daytime or
nighttime frequency, in the absence of a proven urinary infection or other
obvious pathology
2. Urethral pain syndrome – occurrence of recurrent episodic urethral painusually on voiding, with daytime frequency and nocturia, in the absence of a
proven infection or other obvious pathology
3. Vulval pain syndrome / Vaginal pain syndrome / Perineal pain syndrome –occurrence of persistent or recurrent episodic vulval, vaginal or perineal pain
which is either related to the micturition cycle or associated with symptoms
suggestive of urinary tract or sexual dysfunction, with no proven infection orobvious pathology
4. Pelvic pain syndrome – occurrence of persistent or recurrent episodic pelvic pain associated with symptoms suggestive of lower urinary tract, sexual,
bowel or gynecological dysfunction, with no proven infection or obvious
pathology
II. SIGNS SUGGESTIVE OF LOWER URINARY TRACT DYSFUNCTION
1. Daytime frequency – number of voids during waking hour inclusive of the last
void before sleep and the first void upon waking in the morning2. Nocturia – number of voids recorded during a night’s sleep, each void is
-
8/9/2019 CPG Urogynecology
11/71
preceded and followed by sleep
3. Polyuria – urine production of more than 2.8 liters in 24 hours in adults4. Nocturnal polyuria – is present when an increased proportion of the 24-hour
output occurs at night (> 20% in young adults to > 33% over 65 years)
5. Maximum voided volume – largest recorded volume of urine voided in a single
micturition as determined in the bladder diary or frequency/volume chart6. SUI – observation of involuntary leakage from the urethra, synchronous with
exertion/effort, or sneezing or coughing
7. Overactive bladder – characterized by the storage symptoms of urgency withor without urgency incontinence, usually with frequency and nocturia
8. Mixed UI – complaint of involuntary leakage associated with urgency and alsowith effort, exertion, sneezing and coughing
9. Extraurethral incontinence – observation of urine leakage through channelsother than the urethra
10. Uncategorized incontinence – observation of involuntary leakage that cannot be classified into one of the above categories on the basis of signs and
symptoms11. Intravesical pressure – pressure within the bladder12. Abdominal pressure – pressure surrounding the bladder which is estimated
from rectal, vaginal, or less commonly, from extraperitoneal pressure or bowel
stoma13. Detrusor pressure – the component of vesical pressure that is created by
forces in the bladder wall, both active and passive. It is estimated bysubtracting the abdominal pressure from the intravesical pressure.
14. Filling cystometry – method by which the pressure/volume relationship of the bladder is measured during bladder filling
15. Bladder diary – records the times of micturitions and voided volumes,incontinence episodes, pad usage and other information such as fluid intake,
the degree of urgency and the degree of incontinence
16. Detrusor overactivity – a urodynamic investigation characterized byinvoluntary detrusor contractions during the filling phase which may be
spontaneous or provoked
17. Terminal detrusor overactivity – defined as a single, involuntary detrusorcontraction, occurring at cystometric capacity, which cannot be suppressed
and results in incontinence usually resulting in bladder emptying18. Detrusor overactivity incontinence – incontinence due to an involuntary
detrusor contraction
19. Neurogenic detrusor overactivity – involuntary detrusor contractionsoccurring in patients with relevant neurological condition20. Idiopathic detrusor overactivity – no defined cause for the involuntary
detrusor contractions
21. Bladder compliance – describes the relationship between change in bladdervolume and change in detrusor pressure
22. Cystometric capacity – the bladder volume at the end of the fillingcystometrogram when “permission to void” is given. It is the volume voided
together with any residual urine.
23. Maximum cystometric capacity – the volume at which a patient with normalsensations feels she can no longer delay micturition (has a strong desire to
void).24. Urodynamic stress incontinence – noted during filling cystometry and is
-
8/9/2019 CPG Urogynecology
12/71
defined as the involuntary leakage of urine during increased intraabdominal
pressure, in the absence of a detrusor contraction. It replaces the term
”genuine stress incontinence”.
25. Abdominal leak point pressure – the intravesical pressure at which urineleakage occurs due to increased abdominal pressure in the absence of a
detrusor contraction.26. Detrusor leak point pressure – the lowest detrusor pressure at which urine
leakage occurs in the absence of either a detrusor contraction or increased
abdominal pressure
27. Detrusor underactivity – a contraction of reduced strength and/or duration,resulting in a prolonged bladder emptying and/or failure to achieve complete
bladder emptying within a normal time span.
28. Acontractile detrusor – one that cannot be demonstrated to contract duringurodynamic studies.
29. Bladder outlet obstruction – a generic term for obstruction during voiding andis characterized by increased detrusor pressure and reduced urine flow rate
30. Dysfunctional voiding – characterized by intermittent and/or fluctuating flowrate due to involuntary intermittent contractions of the peri-urethral striated
muscle during voiding in neurologically normal individuals.31. Detrusor sphincter dysynergia – a detrusor contraction concurrent with an
involuntary contraction of the urethral and/or peri-urethral striated muscle.32. Non-relaxing urethral sphincter obstruction – occurs in individuals with a
neurological lesion and is characterized as non-relaxing, obstructing urethraresulting in reduced urine flow.
33. Pelvic organ prolapse (POP) – defined as the descent of one or more of theanterior vaginal wall, the posterior vaginal wall, and the apex of the vagina
(cervix/uterus) or vault (cuff) after hysterectomy.
34. Anterior vaginal wall prolapse – defined as the descent of the anterior vaginaso that the urethrovesical junction (a point 3 cm proximal to the external
urethral meatus) or any anterior point proximal to this is less than 3 cm above
the plane of the hymen
35. Posterior vaginal wall prolapse – defined as any descent of the posteriorvaginal wall so that a midline point on the posterior vaginal wall 3 cm above
the level of the hymen or any posterior point proximal to this is less than 3 cm
above the plane of the hymen36. Prolapse of the apical segment of the vagina – defined as any descent of the
vaginal cuff scar (after hysterectomy) or cervix below a point which is 2 cm
less than the total vaginal length above the plane of the hymen37. Rectal prolapse – defined as the circumferential full thickness rectal protrusion beyond the anal margin
38. Anal incontinence – defined as any involuntary loss of fecal material and/orflatus and maybe divided into:
a. Fecal incontinence (FI) – any involuntary loss of fecal material b. Flatus incontinence – any involuntary loss of gas (flatus)
39. Acute retention of urine – defined as a painful, palpable or percussable bladder, when the patient is unable to pass any urine.
40. Chronic retention of urine – defined as a non-painful bladder, which remains palpable or percussable after the patient has passed urine. Such patients may
be incontinent.
-
8/9/2019 CPG Urogynecology
13/71
III. TREATMENT
1. Pelvic floor training – repetitive selective voluntary contraction and relaxation
of specific pelvic floor muscles
2. Biofeedback – technique by which information about a normally unconscious
physiological process is presented to the patient and/or therapist as a visual,auditory or tactile signal
3. Behavioral modification – the analysis and alteration of the relationship
between the patient’s symptoms and her environment for the treatment of
maladaptive voiding patterns
4. Electrical stimulation – the application of electrical current to stimulate the
pelvic viscera or their nerve supply
5. Catheterization – technique for bladder emptying employing a catheter to
drain the bladder or a urinary reservoir
6. Intermittent (in/out) catheterization – defined as drainage or aspiration of the
bladder or urinary reservoir with subsequent removal of the catheter
a. Intermittent self-catheterization – performed by the patient herself b. Intermittent catheterization – performed by an attendant (e.g., doctor,
nurse, or relative)c. Clean intermittent catheterization – use of a clean technique. This
implies ordinary washing techniques and use of disposable or cleansedreusable catheters
d. Aseptic intermittent catheterization – use of a sterile technique. Thisimplies genital disinfection and use of sterile catheters and
instruments/gloves
7. Indwelling catheterization – an indwelling catheter remains in the bladder,
urinary reservoir or urinary conduit for a period of time longer than one
emptying
References
1. Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JOL, Klarskov P, Shull BL, Amith
ARB. The standardization of terminology of female pelvic organ prolapse and pelvic floor
dysfunction. Am J Obstet Gynecol 1996;175:10-1.
2. Abrams P, Cardozo L, Khoury S, Wein A. Incontinence. 4 th International Consultation on
Incontinence. 4th ed. 2009.
-
8/9/2019 CPG Urogynecology
14/71
EVALUATION OF PELVIC FLOOR DYSFUNCTION AND THE
POP-Q SCORING SYSTEMJudith M. Sison, MD, MPH
I. URINARY INCONTINENCE
1. Patients with urinary incontinence (UI) should undergo a basic evaluation
that includes a history1, physical examination
2,3, measurement of post-
void residual volume (PVR), urinalysis, and 3-day bladder chart.
Standard chemical tests for renal function are recommended in patients
with UI and a high probability of renal damage. ( Level II-3, Grade A)
Summary of Evidence
Post-void residual volume
A PVR < 50 ml is considered adequate bladder emptying and > 200 ml isconsidered inadequate.4,5
Routine urinalysis with or without urine culture and sensitivity test
To assess for any lower urinary tract infection (UTI), a clean midstream orcatheterized urine sample should be obtained for dipstick urinalysis which
provides necessary information as a “multi-property” strip should be used.6 It
can also screen any urothelial lesion and stone disease.7
Three-day bladder diary (frequency/volume chart)
Urinary diaries are highly reproducible and correlated well with urodynamic
diagnosis.8
Consistent results have been shown between the first 3-day periodand the last 4-day period, suggesting that a 3-day chart may be adequate to
document symptoms, thus, improving compliance.9, 10
Standard blood chemistries for renal function
The routine use of a battery of common chemical tests in patients with UI
appears to be a prudent rule of good practice in the following conditions:
a. chronic retention with UI (overflow UI) b. neurogenic lower urinary tract dysfunctionc. when surgery is contemplatedd. when there is a clinical suspicion
2. Cough stress test strongly suggests a diagnosis of stress urinary
incontinence (SUI). Borderline or negative test results should be repeated
to maximize its diagnostic accuracy. (Level II-2, Grade B)
Summary of Evidence
Loss of small amounts of urine in spurts, simultaneous with coughingand in the absence of urge, strongly suggests a diagnosis of SUI.11 Prolonged
loss of urine, leaking 5-10 seconds after coughing, or no urine loss with
provocation indicates that other causes of incontinence, especially detrusor
overactivity, may be present. The inability to demonstrate the sign of SUI
-
8/9/2019 CPG Urogynecology
15/71
-
8/9/2019 CPG Urogynecology
16/71
effectively carry out passive contraction therapy, an exercise program, or
any need for further evaluation. (Level III, Grade C)
Summary of Evidence
The continence mechanisms imply that integrity of the levator ani andthe external urethral sphincter is necessary to maintain continence.
It is
therefore important to test the contractility of these muscles.
A pelvic muscle contraction may be assessed by visual inspection,
palpation, electromyography or perineometry. When considering
methods/devices used to measure pelvic muscle strength, cost and availability
are important considerations.21
This can be qualitatively defined by the tone at rest and the strength of
a voluntary contraction as strong, weak, or absent by a validated grading
system, e.g. Oxford scale 1-5. Factors to be assessed include strength,
duration, displacement, and repeatability.22 The modified Oxford scale has
been shown to correlate well with surface electromyography and manometryof pelvic floor muscles.23
7. Urine cytology is recommended in patients with persistent microscopic
hematuria in the absence of UTI to exclude bladder neoplasm. (Level III,Grade C)
Summary of Evidence
Urine cytology should be requested in patients with microscopic
hematuria (RBC 2-5/hpf), ! 50 year-old with persistent hematuria or those
with acute onset of irritative voiding symptoms in the absence of UTI to
exclude bladder neoplasm.24 It is not recommended in the routine evaluation
of patients with incontinence.25
8. Cystometric testing is not required in the routine or basic evaluation of
UI.26
Whenever objective clinical findings do not correlate with or
reproduce the patient’s symptoms, simple cystometry is appropriate for
detecting abnormalities of detrusor compliance and contractibility.27
(Level II, Grade B)
Summary of Evidence
Office cystometry: Retrograde bladder filling provides an assessment
of bladder sensation and an estimate of bladder capacity. The definition of
normal bladder capacity lacks consensus, with values that range from 300-750
ml. In addition, large bladder capacities are not always pathologic.
Researchers showed that 33% of women with bladder capacities > 800 ml.
were urodynamically normal, and only 13% had true bladder atony.28 .
9. Minimum urodynamic investigation includes uroflowmetry, pressure-
flow study of voiding together with one or more of the following, as
indicated for the individual patient: abdominal leak point pressuremeasurement, urethral pressure measurement. (Level II, Grade B)
-
8/9/2019 CPG Urogynecology
17/71
Indications for urodynamics29:
a. Prior to invasive or irreversible treatment or retreatment of all types of
incontinence
b. Complex incontinence cases whenever there is doubt about the
underlying pathophysiology
c. Neurogenic bladders as an initial assessment or as part of a long-termsurveillance. If possible, videourodynamic testing should be employed.
Summary of Evidence
There was not enough evidence to show whether women with UI who
underwent urodynamics were less likely to be incontinent after treatment than
women who did not undergo urodynamic testing.30, 31
10. Urethral pressure profilometry (UPP) and leak point pressure
measurements have not proved useful in the evaluation of UI. (Level III,
Grade C)
Summary of Evidence
Researchers found that UPP is not standardized, reproducible, or ableto contribute to the differential diagnosis in women with SUI symptoms.
Therefore it does not meet the criteria for a useful diagnostic test.32
Leak point pressure measures the amount of increase in intraabdominal pressure that
causes stress incontinence, although its usefulness also has not been proved.33
11. Cystoscopy should not be performed routinely in patients with
incontinence to exclude neoplasm. (Level II-2, Grade B)
Summary of Evidence
Indications for cystoscopy in patients with UI include those who have:
sterile hematuria or pyuria; irritative voiding symptoms, e.g. frequency,
urgency, urge incontinence in the absence of any reversible causes; bladder
pain; recurrent cystitis; suburethral mass; and when urodynamic testing fails toduplicate symptoms of UI.34 Bladder lesions are found in < 2% of patients
with incontinence35
; therefore, cystoscopy should not be performed routinely
in patients with incontinence to exclude neoplasm
36
.
12. Imaging: Ultrasound is not recommended in the primary evaluation of
patients with UI and/or POP. It is likewise an optional test in the
evaluation of patients with complex or recurrent UI and or POP.37, 29
MRI of the pelvic floor is rapidly gaining field in the evaluation of
enteroceles and in the morphological analysis of pelvic floor muscles
although the evidence of its clinical benefit is still unclear.29,38 (Level III,
Grade C)
-
8/9/2019 CPG Urogynecology
18/71
Summary of Evidence
Transabdominal, perineal or translabial, transrectal, and transvaginal
ultrasound is currently used due to its noninvasive nature, ready availability,
and absence of distortion. Although ultrasound is rapidly evolving and much
progress has been made, it remains optional as evidence of its clinical benefitis still weak.
29
MRI provides anatomical detail to the pelvic floor in a single non-
invasive study that does not expose the patient to ionizing radiation. Gousse,
et. al. reported a sensitivity of 83%, specificity of 100%, positive predictive
value of 100%, when comparing dynamic MRI to intraoperative findings.
These numbers were similar compared to physical examination alone.39
II. PELVIC ORGAN PROLAPSE AND PELVIC ORGAN PROLAPSE
QUANTIFICATION SYSTEM
1. The only symptom specific to prolapse is the awareness of vaginal bulge
or protrusion. For all other pelvic symptoms, resolution with prolapse
treatment can not be assumed.40
(Level II-3, Grade A)
Summary of Evidence
Almost half of parous women can be identified as having prolapse by
physical examination criteria, most are not clinically affected; the finding is
not well correlated with specific pelvic symptoms.41
2. The amount or severity of prolapse in each vaginal segment may be
measured and recorded using the pelvic organ prolapse quantification
system (POP-Q). (Level III, Grade C)
Summary of Evidence
The POP-Q system was introduced for use in clinical practice and
research. Some have argued that the 9-points of the POP-Q system maybemore detailed than necessary for clinical practice, and it is better suited for
clinical research purposes. It often is useful to include a measurement of the
extent of protrusion relative to the hymen to better assess change overtime.
42
2. Cystoscopy or cystourethroscopy should be performed intraoperatively to
assess for bladder or ureteral damage after all prolapse or incontinence
procedures during which the bladder or ureters may be at risk of
injury.43 (Level II-2, Grade B)
Summary of Evidence
A recent systematic review of urinary tract injuries during
urogynecologic surgical procedures and routine intraoperative
cystourethroscopy reported the overall ureteral injury rate was 8.8/1,000
-
8/9/2019 CPG Urogynecology
19/71
procedures (95% CI 2.3-12.6).43 The overall bladder injury rate after
urogynecologic surgical procedures was 16.3 (95% CI 4.3-26.6).44
PELVIC ORGAN PROLAPSE QUANTIFICATION SYSTEM (POP-Q)
The POP-Q is the current gold standard for measuring prolapse stage in patients. It offers an objective evaluation that can be communicated between
physicians and used to compare pre- and post-surgical intervention examinations. It
was developed and adopted by the International Continence Society (ICS) and
endorsed by leading international organizations dealing with pelvic floor dysfunction.
Stages are based on the maximal extent of prolapse relative to the hymen, in one
or more compartments. The hymen is assigned the value of zero; points proximal to
the hymen are negative (inside the body) while points distal to the hymen are positive
(outside of the body). There are 6 vaginal sites as represented in the POP-Q grid, and
3 additional measurements which always have a positive value namely: a) genital
hiatus (Gh) b) perineal body (Pb), and c) total vaginal length (TVL). Allmeasurements, except for TVL, are made while patient is doing Valsalva maneuver.
All measurements are made to the nearest 0.5 cm. Both the patient’s position(lithotomy, birthing chair, or standing) during the examination, and the state of her
bladder and rectum (full or empty) should be noted.
Quantification Definitions and Ranges:POINT MEASUREMENT RANGE
Aa Anterior vaginal wall 3 cm proximal to hymen -3 to +3
Ba Leading-most point of anterior vaginal wall prolapse -3 to + TVL
C Most distal edge of cervix or vaginal cuff (if absent cervix) - /+ TVL
D Most distal portion of posterior fornix - /+ TVL
Ap Post vaginal wall 3 cm proximal to hymen -3 to +3
Bp Leading-most point of post vaginal wall prolapse -3 to + TVL
Gh Perpendicular distance from mid-urethral meatus to posterior hymen No limit
Pb Perpendicular distance from mid-anal opening to posterior hymen No limit
TVL Post vaginal fornix or vaginal cuff (if absent cervix) to the hymen No limit
The stages of POP are:
Stage 0 – No descent of any compartment
Stage 1 – Descent of the most prolapsed compartment between perfect support and
-1 cm
Stage 2 – Descent of the most prolapsed compartment between -1 cm and +1 cmStage 3 – Descent of the most prolapsed compartment between +1 cm and TVL -2
cmStage 4 – Descent of the most prolapsed compartment from TVL -2 cm to complete
prolapse
-
8/9/2019 CPG Urogynecology
20/71
Reproduced from: Bump RC, et al. The standardization of terminology of female pelvic organ prolapse
and pelvic floor dysfunction. Am J Obstet Gynecol 1996; 175: 10-7.42
III. FECAL INCONTINENCE
1. A simple assessment of possible anorectal dysfunction by history and
physical examination should be performed whenever lower urinary tract
function is evaluated. (Level III, Grade C)
Summary of Evidence
Jackson, et. al. evaluated 247 women with either UI or POP. Thirty
one percent (31%) of women with UI and 7% with POP had concurrent anal
incontinence.45
2. The cheapness and speed of investigation makes endosonography the
ideal screening procedure to assess anal sphincter. Manometry may offer
little extra information where ultrasound is available. Preoperative
assessment in patients with possible atrophy is the main indication for
MRI.21 (Level III, Grade C)
-
8/9/2019 CPG Urogynecology
21/71
Summary of Evidence
Anorectal manometry is an optional test that may be used in difficult-
to-evaluate cases of fecal or anal incontinence. It should be considered if
therapy based on simpler assessments fails to yield the desired improvement.46
MRI is superior to ultrasound in diagnosis of perianal sepsis and inquantifying external anal sphincter muscle degeneration.
47
References
1. Scientific Committee of the First International Consultation on Incontinence. Assessment and
treatment of urinary incontinence. Lancet 2000;355:2153-8.
2. Ouslander JG, et al. Incontinence in the nursing home. Ann Intern Med 1995;122:438-49.
3. Blaivas JG, et al. The bulbocavernosus reflex in urology: a prospective study of 299 patients.
J Urol 1981;126:197-9.
4. Agency for Health Care Policy and Research. Urinary incontinence in adults: acute and
chronic management. Clinical Practice Guideline, No.2, 1996 Update. AHCPR Publication No. 96-0682. Rockville (MD): AHCPR; 1996.
5. Goode PS, et al. Measurement of postvoid residual urine with portable transabdominal bladder
ultrasound scanner and urethral catheterization. Int Urogynecol J Pelvic Floor Dysfunct
2000;11(5):296-300.
6. Semeniuk H, et al. Evaluation of the leukocyte esterase and nitrite urine dipstick screening
tests for detection of bacteriuria in women with suspected uncomplicated urinary tract
infections. J Clin Microbiol 1999; 37(9):3051-2.
7. European Urinalysis Guidelines. Summary. Scand J Clin Lab Invest 2000;60:1-96.
8. Wyman JF, et al. The urinary diary in evaluation of incontinent women: a test-retest analysis.
Obstet Gynecol 1988;71:812-7.
9. Nygaard I, et al. Reproducibility of a 7-day voiding diary in women with stress urinary
incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:15-7.
10. Addla S, et al. Assessment of reliability of 1-day, 3-day, and 7-day frequency volume charts. Eur Urol 2004;(Suppl 2):30.
11. Wall LL, et al. Simple bladder filling with a cough stress test compared with subtracted
cystometry for the diagnosis of urinary incontinence. Am J Obstet Gynecol 1994;171:1472-7;
discussion 1477-9.
12. Swift SE, Ostergard DR. Evaluation of current urodynamic testing methods in the diagnosis of
genuine stress incontinence. Obstet Gynecol 1995;86:85-91.
13. Karram MM, Bhatia NN. The Q-tip test: Standardization of the technique and its
interpretation in women with urinary incontinence. Obstet Gynecol 1988;71(61):807-11.
14. Walters MD, et al. Q-tip test: a study of continent and incontinent women. Obstet Gynecol
1987;70(2):208-11.
15. Bergman A. Invalidity of Marshall-Marchetti and Bonney stress tests. In: Ostergard D, Bent
A, eds. Urogynecology and urodynamics: Theory and practice (2e) Baltimore, MD: Williams
and Wilkins, 1991:179-84.
16. Kromann-Andersen B, et al. Pad-weighing tests; A literature survey on test accuracy and
reproducibility. Neurourol Urodyn 1989;8(3):237-42.
17. Jorgensen L, Lose G, et al. Diagnosis of mild stress incontinence in females: 24-hour pad
weighing test vs. the 1-hour test. Neurourol Urodyn 1987;6:165-6.
18. Kinn AC, Larsson B. Pad test with fixed bladder volume in urodynamic stress incontinence.
Acta Obstet Gynecol Scand 1987;66(4): 369-371.
19. Artibani W, et al. Imaging and other investigations. In: Abrams P, Cardozo L, Khoury S,Wein A (eds) Incontinence. Plymouth: Health Publication, 2002:425-77.
20. Raghavaiah N. Double-dye test to diagnose various types of vaginal fistulas. J Urol 1974;112: 811-2.
21. 4th International Consultation on Incontinence, Paris July 5-8, 2008. Incontinence edited byAbrams, Cardozo, et al. Health Publication Ltd. 4
th edition 2009
22. Laycock J, et al. Pelvic floor assessment: the PERFECT scheme. Physiotherapy 2001;87:631-42.
-
8/9/2019 CPG Urogynecology
22/71
23. Haslam J. Evaluation of pelvic floor muscle assessment: digital, manometric, and surfaceelectromyography in females. M Phil Thesis. University of Manchester, 1999.
24. Cohen RA, et al. Clinical Practice. Microscopic hematuria. N Eng J Med 2003;348:2330-8.
25. Chahal, et al. Is it necessary to perform urine cytology in screening patients with hematuria?
Eur Urol 2001;39:283-6.
26. ACOG 2007 Compendium Vol.11 Practice Bulletins pp1115-27.
27. Wall LL, et al. Simple bladder filling with a cough stress test compared with subtractedcystometry for the diagnosis of urinary incontinence. Am J Obstet Gynecol 1994;171:1472-7;
discussion 1477-9.
28. Weir J, et al. Large-capacity bladder. A urodynamic survey. Urology 1974;4:544-8.
29. Cardoso A, et. al. (ed). Incontinence. 4th
International Consultation on Incontinence Paris July
5-8, 2008. Health Publication Ltd. 4th
edition, 2009.
30. Ramsay IN, et al. A randomized controlled trial of urodynamic investigations prior to
conservative treatment of urinary incontinence in the female. Int Urogynecol J 1995;6:277
31. Khullar V, Cardozo L, et al. 30th
Annual meeting of ICS, Finland 2000.
32. Weber AM. Is urethral pressure profilometry a useful diagnostic test for stress urinary
incontinence? Obstet Gynecol Surv 2001;56:720-35.
33. Weber AM. Leak point pressure measurement and stress urinary incontinence. Curr Women’s
Health Rep 2001;1:45-52.
34. Association of Professors of Gynecology and Obstetrics. Clinical management of urinaryincontinence. Crofton (MD) APGO; 2004.
35. Awad SA, et al. Final diagnosis and therapeutic implications of mixed symptoms of urinary
incontinence in women. Urology 1992;39:352-7.
36. Agency for Health Care Policy and Research. Urinary incontinence in adults: acute and
chronic management. Clinical Practice Guideline, No.2, 1996 Update.AHCPR Publication
No. 96-0682. Rockville (MD): AHCPR; 1996.
37. Beer-Gabel M, et al. Dynamic transperineal ultrasound in the diagnosis of pelvic floor
disorders: pilot study. Dis Colon Rectum 2002;45:239-45.
38. Pannu HK, et al. Dynamic MR imaging of pelvic organ prolapse: spectrum of abnormalities.
Radiographics 2000;20:1567-82.
39. Gousse AE, et al. Dynamic half fourier acquisition single shot turbo spin-echo magnetic
resonance imaging for evaluating the female pelvis. J Urol 2000;164:1606-13.
40. ACOG Compendium of Selected Publications 2009. Clinical Management Guidelines forObstetrician-Gynecologists #85, September 2007: 417-29.
41. Samuelsson EC, et al. Signs of genital prolapse in a Swedish population of women 20-59
years of age and possible related factors. Am J Obstet Gynecol 1999;180:299-305.
42. Bump RC, et al. The standardization of terminology of female pelvic organ prolapse and
pelvic floor dysfunction. Am J Obstet Gynecol 1996;175:10-7.
43. Gustilo-Ashby AM, et al. The incidence of ureteral obstruction and the value of intraoperative
cystoscopy during vaginal surgery for POP. Am J Obstet Gynecol 2006;194:1478-85.
44. Gilmour DT, et al. Rates of urinary tract injury from gynecologic surgery and the role ofintraoperative cystoscopy. Obstet Gynecol 2006;107:1366-72.
45. Jackson S, Walters M, et al. Fecal incontinence in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol 1997;89:423-7.
46. De Leeuw JW, et al. Relationship of anal endosonography and manometry to anorectal
complaints. Dis Colon Rectum 2002;45:1004-10.47. Rociu E, et al. Fecal Incontinence: endoanal ultrasound vs endoanal MR imaging. Radiology
1999; 212(2):453-8.
48. Cardozo L, Staskin D (Eds). Textbook of Female Urology and Urogynecology 2006; 2 nd edition Volume 1.
49. Chappe C, et. al. Multidisciplinary Management of Female Pelvic Floor Disorders 2006.
-
8/9/2019 CPG Urogynecology
23/71
CONSERVATIVE MANAGEMENT OF STRESS URINARY
INCONTINENCE Almira J. Amin-Ong, MD.
Urinary incontinence (UI) affects women not only in the reproductive age butmore commonly in the postmenopause. It is often a neglected condition even if the
prevalence rate is quite high ranging from 17-55% in older and 12-42% in youngerwomen. Majority do not seek consult but opt to make provisions in their daily routine
to hide or live with the disorder thus affecting the overall quality of life.The International Continence Society (ICS) describes three major categories
of incontinence – stress, urge and mixed. Differentiating among the three types wouldhelp the primary care physician gear management towards that which will be
beneficial to the patient. There are several management schemes available for UI.
Conservative management alone entails numerous forms of intervention, which are
usually low cost and with low adverse effects. With the current crisis putting a strain
on the health care of most economies, conservative management is offered as anoption especially on the following circumstances: those awaiting or delaying surgery,
those in whom existing medical condition precludes any form of surgical intervention,
and those whose symptoms are not severe enough for surgical intervention.
I. LIFESTYLE INTERVENTION
There are very few randomized controlled trials (RCTs) on the field of
lifestyle intervention to control, prevent or improve UI. None of those availablespecifically addresses the impact of age or any other variables on outcome.
1. Women with a body mass index (BMI) of 30 or more should be
encouraged weight reduction as this significantly reduces prevalence of
UI. (Level II-1, Grade A)
Summary of Evidence
Obesity is an independent risk factor for UI even after controlling for
age and parity. In women with BMI of 30 or higher, the odds of severe urinary
incontinence were 3.1 times that of women with BMI between 22 and 241.
Another study found a 2.39 fold risk of UI compared with normal weightwomen.2 A 2005 RCT involving 48 participants showed that women who
were put on a liquid diet showed a 60% reduction of weekly incontinent
episodes and a weight loss of 15 kgs.3 Another RCT by the same author
involving 338 women (the Programme to Reduce Incontinence by Diet and
Surgery – [PRIDE]) who underwent a 6-month intensive weight loss program
showed a weekly incontinence episode reduction of 70% as compared to 22%
in the control group.4
2. Heavy lifting may predispose to development of UI. (Level III, Grade B)
-
8/9/2019 CPG Urogynecology
24/71
Summary of Evidence
There are no RCTs comparing heavy lifting with sedentary activities.
The association between heavy lifting and UI should be investigated further,
whether heavy exertion is a risk factor for incontinence or whether changing
exertions can improve existing incontinence. Present studies are conflictingwith one study of 27,936 women in 2003 reporting no difference in UI
between women engaged in high impact activities more than 2 hours per week
with those who engaged in less than 1 hour of activity per week.5 Nygard, et.
al., in a study of 3,364 women reported that UI with physical activity was
more common among highly active than less active women (15.9% versus
11.8%; p=0.01).6
3. Smoking increases the risk of more severe UI. (Level III, Grade B)
Summary of Evidence
There are currently no RCTs regarding the effect of smoking cessation
on resolution or promotion of the onset of UI. Current data are conflictingwith one in vitro study stating that nicotine produces phasic contraction of the
bladder musculature inducing the urge type of incontinence.7 A large study
involving 27,936 women found that smoking increases the odds of severe UI
(Odds Ratio [OR] 1.4, 95% CI 1.2-1.6). However, smokers were found tohave stronger urethral sphincters.5
4. Decreasing caffeine intake improves continence. (Level II-1, Grade B)
Summary of Evidence
Bryant, et. al. found that decreasing caffeine intake to 96.5 mg had
statistically significant reduction in urgency episodes (61% versus 12%) and
number of incontinence episodes (55% versus 26%) but this was not
statistically significant.8 In the Norwegian EPICONT Study, they found that
tea drinkers had higher odds of UI (OR 1.2, 95% CI 1.4-55) for up to 2 cups
per day and an OR of 1.3 (95% CI 1.5-19.0) for 3 or more cups compared tonone.5
4. Alcoholic beverages do not increase the incidence of UI. (Level II-2, Grade B)
Summary of Evidence
Large epidemiologic trials using multivariate analyses assessed the
effect of alcohol consumption and UI but found no association between the
two even after adjusting for age and fluid intake.9
5. Limiting fluid intake to prevent UI should only be reserved to those with
abnormally high intake. (Level III, Grade C)
-
8/9/2019 CPG Urogynecology
25/71
Summary of Evidence
It is always the assumption that leakages can very well be controlled
by limiting the fluid intake. However, a state of negative fluid balance or poor
fluid intake may lead to urinary tract infections (UTIs), constipation or
dehydration – conditions that can readily be prevented by maintaining theaverage daily fluid intake. An RCT that used a small crossover design foundthat when fluid intake is decreased, women with stress urinary incontinence
(SUI) and women with detrusor overactivity had decreased incontinence
episodes10
.
6. Chronic straining may be a risk factor for development of UI. (Level III,
Grade C)
Summary of Evidence
There are no studies regarding the effect of resolving constipation orregulating bowel function on incontinence. One study reported that women
who strain during defecation are more likely to report SUI (OR 1.9, 95% CI1.3-2.6) and urgency (OR 1.7, 95% CI 1.2-2.4).11 Further research is needed
to evaluate the role of constipation or chronic straining in the pathogenesis ofUI.
7. Postural changes such as crossing the legs and bending forward might be
useful in reducing leakages during coughing or provocation. (Level III,
Grade C)
Summary of Evidence
There was a mean fluid loss of only 1.3 g (95% CI 0.5-2.1, p
-
8/9/2019 CPG Urogynecology
26/71
Summary of Evidence
Studies regarding PFMT are conflicting because of variations in the
technique used. However, the most recent Cochrane systematic review (2003)
which included studies of women with urge, stress or mixed type of
incontinence found that PFMT was more effective compared to placebointervention (drug, sham electrical stimulation, sham exercise).
13 Compared
with vaginal cones, there was a significant reduction in urinary leakage with
PFMT alone. There is also no benefit of combining PFMT with biofeedback.
PFMT supervised and continued for 3 months is a safe and effective treatment
for stress and mixed types of incontinence.
III. ELECTRICAL STIMULATION
Electrical stimulation for patients with stress or mixed type of
incontinence does not offer any benefit in reducing the frequency ofincontinent episodes. (Level I, Grade B)
Summary of Evidence
Electrical stimulation involves delivery of brief electrical impulses via
needle or surface electrodes to the sacral nerves to inhibit detrusor overactivityand to improve pelvic floor musculature. A randomized trial of 68 women
with urge type of incontinence did not reveal significant improvement at all.
For women with stress type of incontinence, a small trial of 26 women showed
no changes in urinary leakages per week based on an incontinence impact
questionnaire. Combined with PFMT, a recent trial of 200 women showed no
significant reduction in the frequency of incontinent episodes.9
IV. MAGNETIC STIMULATION
The benefit of magnetic stimulation for treatment of UI has not been
established. (Level II-3, Grade D)
Summary of Evidence
Extracorporeal magnetic stimulation is delivered to the pelvic floor
muscles and the sacral nerve roots by sitting on a magnetic chair. The patient’s
perineum is centered on the middle of the seat from where the pelvic floor
muscles are placed directly on the primary axis of the pulsating magnetic field
without any vaginal or anal probes. Usually, the treatment is given for 16
sessions for 6 weeks. There are still no trials regarding primary and secondary
prevention of UI. Regarding treatment, magnetic stimulation might be better
for both stress and urge type of incontinence.14,15 Further investigation is
warranted.
-
8/9/2019 CPG Urogynecology
27/71
V. VAGINAL CONES
Vaginal cones offer subjective cure but do not lead to significant
improvement on the number of leakage episodes, pad test or pelvic floor
muscle strength. (Level II-1, Grade B)
Summary of Evidence
Vaginal cones are a set of weighted cylinders that are held in place by
contraction of the pelvic floor muscles. Therapy usually starts with the lightest
cone then graduated to the heavier ones. It is not readily available in our
country. Majority of the trials enrolled women with stress incontinence who
had subjective cure from UI.16 Compared with the control group who had
other forms of intervention, there were no differences in objective outcomes –
leakage episodes, pad test or pelvic floor muscle strength.16,17
VI. BLADDER TRAINING
Bladder training combined with pelvic floor muscle training is more
effective than either alone. It should be offered as first line treatment for
urge or mixed type of incontinence. (Level I, Grade A)
Summary of Evidence
Bladder training is a technique to increase the time interval between
voids using progressive voiding schedules. It is usually advised on patients
who have intact cognitive and physical functions and can take months to
achieve a cure. There are not too many trials to support bladder training. There
were two small trials with 78 patients which showed few subjective cures in
patients who had bladder training alone versus those who did not receive any
at all (OR for failure, 0.07; 95% CI 0.03-0.19). However, when one combines
it with PFMT, it is more effective than a combination of bladder training with
drug therapy. There is good evidence though that bladder training is effective
for urge or mixed type of incontinence, with fewer adverse effects and lowerrelapse rates compared to drug treatment with antimuscarinics.13
VII. PHARMACOLOGIC
Anticholinergics are effective in the treatment of urge incontinence. (Level
1, Grade A)
Summary of Evidence
Anticholinergics are drugs prescribed to inhibit involuntary detrusor
contractions that could lead to urine leakages. A Cochrane systematic review
found that anticholinergics were better than placebo in subjective cure rate and
improvement rates (RR 1.41; 95% CI 1.29-1.54) and in improvement inleakages episodes in 24 hours (WMD, -0.56; 95% CI -0.73 to -0.39).18 When
-
8/9/2019 CPG Urogynecology
28/71
compared with other drugs used to treat urge incontinence, anticholinergics
still offer both subjective cure and improvement in leakage episodes.
References
1. Danforth KN, Townsend MK, Lifford K, Curhan GC, Resnick NM, Grodstein F. Risk factors
for urinary incontinence among middle-aged women. Am J Obstet Gynecol 2006;194(2):339-
45.
2. Melville JL, Katon W, Delaney K, Newton K. Urinary incontinence in US women: a
population-based study. Arch Intern Med 2005;165(5):537-42.
3. Subak LL, Whitcomb E, Shen HUI, Saxton J, Vittinghoff E, Brwon JS. Weight loss: a novel
and effective treatment for urinary incontinence. J Urol 2005;174(1):190-5.
4. Subak LL, Wing R, Smith West D, et al, A behavioral weight loss program significantly
reduces urinary incontinence episodes in overweight and obese women [Oral presentation].
American Uroynecologic Society Annual Meeting 2007.
5. Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S. Are smoking and other lifestyle factors
associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG
2003;110(3);247-54.6. Nygaard I, Girts T, Fultz NH, Kinchen K, Pohl G, Sternfeld B. Is urinary incontinence a
barrier to exercise in women? Obstet Gynecol 2005;106(2);307-14.
7. Hisayama T, Shinkai M, Takayanagi I, Toyoda T. Mechanism of action of nicotine in isolated
urinary bladder of guinea-pig. Br J Pharmacol 1988;95(2):465-72.
8. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary
symptoms. Br J Nurs 2002;11(8):560-5.
9. Abrams P, Cardozo L, Kouri S, Wein A: Incontinence. Adult Conservative Management of
Urinary Incontinence. 4th International Consultation in Continence July 2009.
10. Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in
women. J Urol 2005l;174(1):187-9.
11. Moller L, Lose G, Jorgensen T: Risk factors for lower urinary tract symptoms in women 40 to
60 years of age. Obstet Gynecol 2000;96(3):446-51.12. Norton PA, Baker JE: Postural changes can reduce leakage in women with stress urinary
incontinence. Obstet Gynecol 1994;85(5):770-4.
13. Hay-Smith EJ, Bo K, Berghmans LC, et al. Pelvic floor muscle training for urinary
incontinence in women. Cochrane Database Syst Rev 2003, Issue 1.
14. But I, Faganelj M, Sostaric S: Functional magnetic stimulation for mixed urinary
incontinence. J Urol 2005;173(5):1644-46.
15. Morris AR, O’Sullivan R, Dunkley P, Moore KH. Extracorporeal magnetic stimulation is of
limited clinical benefit to women with idiopathic detrusor overactivity: A randomized sham
controlled trial. Eur Urol 2007;52:876-83.
16. Herbison P, P levnik S, Mantle J. Weighted vaginal cones for urinary incontinence. Cochrane
Database Syst Rev 2003, Issue 1.
17. Williams KS, Assassa RP, Gilleis CL, Abrams KR, Turner DA, Shaw C, et al. A randomized
controlled trial of the effectiveness of pelvic floor therapies for urodynamic stress and mixed
incontinence. BJU Int 2006;98(5):1043-50.
18. Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinergic drugs versus placebo for
overactive bladder syndrome in adults. Cochrane Database Syst Rev 2003, Issue 1.
19. Holroyd-Leduc JM, Straus S. Management of urinary incontinence in women: scientific
review. JAMA 2004;291(8):986-95.
-
8/9/2019 CPG Urogynecology
29/71
-
8/9/2019 CPG Urogynecology
30/71
II. OPEN BURCH COLPOSUSPENSION
1. Open retropubic colposuspension can be recommended as an effective
treatment for primary SUI, which has longevity. (Level I, Grade A)
Summary of Evidence
Randomized trials comparing the open colposuspension with anterior
colporrhaphy, the MMK procedure, needle suspension procedures, abdominal
paravaginal repair, traditional sling procedures, the TVT, the transobturator
tape, and laparoscopic colposuspension include 4161 women with 1900
randomized to colposuspension. Analysis shows objective cure rates ranging
from 59% to 100% (median 80%) and subjective cure rates from 71% to 100%
(median 88%). The results from these studies show that the open
colposuspension has objective and subjective outcomes comparable to both
traditional sling procedures and to newer minimally-invasive mid-urethral
sling procedures. However, the colposuspension had better outcomescompared to the anterior colporrhaphy, the MMK, bladder neck needle
suspension, and paravaginal repair.
2. Although open colposuspension has to some extent been replaced by less
invasive mid-urethral slings, it should still be considered for those women
in whom an open abdominal procedure is required concurrently with
surgery for SUI. (Level I, Grade A)
Summary of Evidence
Abdominal retropubic urethropexy or colposuspension procedures,
particularly the Burch colposuspension, have become the gold standard for
treatment of primary or recurrent SUI. Main indications include primary and
secondary urethral sphincter incompetence, with or without a
cystourethrocele, but with adequate vaginal mobility and capacity. The
paravaginal tissues on either side of the bladder neck and bladder base are
sutured and attached to the ipsilateral iliopectineal ligament. The
colposuspension is most successful in patients with pure SUI withhypermobility of the urethrovesical junction. The colposuspension had better
outcomes compared to the anterior colporrhaphy, the MMK, bladder neck
needle suspension, and paravaginal repair.
3. The MMK procedure is not recommended for the treatment of SUI.
(Level I, Grade A)
Summary of Evidence
Randomized trials comparing the open colposuspension with anterior
colporrhaphy, the MMK procedure, needle suspension procedures, abdominal
paravaginal repair, traditional sling procedures, the TVT, the transobturator
tape, and laparoscopic colposuspension include 4161 women with 1900
randomized to colposuspension. The studies showed that colposuspension had
-
8/9/2019 CPG Urogynecology
31/71
better outcomes compared to the anterior colporrhaphy, the MMK, bladder
neck needle suspension, and paravaginal repair.
4. Bladder neck needle suspension procedures are not recommended for the
treatment of SUI. (Level I-II Grade A)
Summary of Evidence
Randomized trials comparing the open colposuspension with anterior
colporrhaphy, the MMK procedure, needle suspension procedures, abdominal
paravaginal repair, traditional sling procedures, the TVT, the transobturator
tape, and laparoscopic colposuspension include 4161 women with 1900
randomized to colposuspension. The studies showed that colposuspension had
better outcomes compared to the anterior colporrhaphy, the MMK, bladder
neck needle suspension, and paravaginal repair.
5. Paravaginal defect repair is not recommended for the treatment of SUIalone. (Level II-1, Grade A)
Summary of Evidence
Randomized trials comparing the open colposuspension with anterior
colporrhaphy, the MMK procedure, needle suspension procedures, abdominal paravaginal repair, traditional sling procedures, the TVT, the transobturator
tape, and laparoscopic colposuspension include 4161 women with 1900
randomized to colposuspension. The studies showed that colposuspension had
better outcomes compared to the anterior colporrhaphy, the MMK, bladder
neck needle suspension, and paravaginal repair.
III. LAPAROSCOPIC BURCH COLPOSUSPENSION
1. Laparoscopic colposuspension is not recommended for the routine
surgical treatment of SUI in women. (Level I-II, Grade A)
Summary of Evidence
The laparoscopic approach has been compared to the standard openBurch colposuspension and the more recent mid-urethral slings, in particular
the TVT. Since 1997, there have been 10 randomized controlled trials (RCTs)
comparing laparoscopic colposuspension with the open colposuspension and 8
with the mid-urethral slings. Although studies included in the Cochrane
review had various lengths of follow-up (majority had follow-up of 6-18
months), subjective cure rates ranged from 58% to 96% in the open technique
and 62% to 100% in the laparoscopic approach, with a nonsignificant 5%
lower relative subjective cure rate for laparoscopic colposuspension (RR 0.95,
95% CI 0.90-1.00).
The objective cure rate, as determined by cough stress testing or pad
test within 18 months, was statistically lower following the laparoscopictechnique (RR 0.91, 95% CI 0.86-0.96). Following urodynamic testing,
-
8/9/2019 CPG Urogynecology
32/71
however, the open colposuspension had significantly higher success rates (RR
0.91, 95% CI 0.85- 0.99).
Studies comparing laparoscopic colposuspension with minimally
invasive mid-urethral slings (TVT) show no statistically significant difference
in subjective cure rates within 18 months (RR 0.91, 95% CI 0.80 to 1.02). The
overall objective cure rate, however, was higher for mid-urethral slings.A systematic review on laparoscopic colposuspension and TVT
showed evidence to favor the mid-urethral sling as the minimal-access
technique of choice for USI.
2. Laparoscopic colposuspension may be considered for the treatment of
SUI in women who also require concurrent laparoscopic surgery for
other reasons. (Level I-II, Grade B)
3. Laparoscopic colposuspension should only be carried out by surgeons
with specific training, expertise, and appropriate workload in
laparoscopic surgery and with expertise in the assessment andmanagement of UI in women. (Level I, Grade A)
IV. TRADITIONAL SLING PROCEDURE
1. Autologous fascial sling is recommended as an effective long-lasting
treatment for SUI. (Level I, Grade A)
Summary of Evidence
Trials on suburethral slings have compared this procedure with open
abdominal retropubic suspension (MMK and Burch colposuspension), needle
suspension, and even the TVT. Studies comparing different sling materials are
also numerous. In comparison with open colposuspension, the objective cure
rate from sling operations was not significantly different within the first year
(Relative Risk [RR] 0.19; 95% CI 0.02-1.53) or on longer follow-up (RR 0.49;
95% CI 0.17-1.42). In the largest RCT study done by Albo, et. al. comparing
colposuspension and fascial sling, the combined subjective and objectiveoutcome in terms of any incontinence (38% vs 47%, p=0.01) and SUI (49% vs
66%, p=
-
8/9/2019 CPG Urogynecology
33/71
may be synthetic or biological. The autologous sling may be harvested from
either the rectus fascia (as initially described by Aldridge in 1942) or fascia
lata. Recently, sling procedures have been done using allograft material
(cadaveric fascia or dura mater), xenograft (porcine dermis and small
intestinal mucosa or bovine fascia) or synthetic material (such as merselene or
prolene). The sling is placed at the level of the bladder neck and proximalurethra (in contrast to the minimally invasive mid-urethral slings) thru acombined vaginal and abdominal route. Complications include vaginal erosion
(0-16%), urethral erosion (0-15%), de novo detrussor instability (3.7-66%),
and voiding difficulties (10.8%).5
Studies comparing autologous rectus fascial sling with TVT involve a
total of 284 patients from 3 RCTs.11,13,14
Cure rates at 12 months range from
83% to 88% after TVT and 81% to 93% after fascial sling.
3. Further high quality research is required to clarify the place of
traditional sling procedures in relation to other procedures and to
establish the optimum sling materials.
V. MID-URETHRAL SLINGS
1. Retropubic mid-urethral slings (TVT) are recommended as an effective
treatment for SUI. (Level I-II, Grade B)
Summary of Evidence
Mid-urethral slings are performed via the retropubic approach (e.g.
TVT, IVS, and SPARC) or via the transobturator approach (e.g. transobturator
tape [TOT] and tension-free vaginal tape-obturator [TVT-O]). The TVT is a
modification of the traditional sling procedure that was introduced by
Ulmsten, et. al. in 1996.15 The procedure, initially described to be performed
in an ambulatory setting, has been compared to more traditional surgical
procedures (such as burch colposuspension and traditional sling procedure)
and is seemingly the new “standard” to which other mid-urethral slings are
compared.
2. TVT is equally effective as colposuspension and traditional sling
procedures. (Level I-II)
Summary of Evidence
Several randomized trials and cohort studies show that there is no
significant difference in the cure rates for the TVT procedure compared to the
Burch colposuspension and the fascial sling. Available literature suggests that
the TVT has short- and medium-term efficacy (cure rate of 63% to 97%)
similar to the open Burch colposuspension but is associated with shorter
operating time and hospital stay, less postoperative voiding dysfunction, and
quicker recovery. The TVT however appears to have significantly more
bladder perforations (6% versus 1%, RR 4.24, 95% CI 1.71-10.52) comparedto the open retropubic colposuspension. The TVT is also equally effective as
-
8/9/2019 CPG Urogynecology
34/71
-
8/9/2019 CPG Urogynecology
35/71
techniques (periurethral or transurethral). However, the group felt that the
studies were small and of moderate quality such that meta-analysis was not
appropriate. Currently, greater subjective improvement was observed after
conventional surgery. Studies comparing bulking agents with non-surgical
therapy or minimal access surgery are lacking.
2. Women should be made aware of alternative minimally invasive
procedures.
References
1. Meschia M, Pifarotti P, Spennacchio M, Buonaguidi A, Gattei U, and Somigliana E. Arandomized comparison of tension-free vaginal tape and endopelvic fascia plication in women
with genital prolapse and occult stress urinary incontinence. Am J Obstet Gynecol
2004;190:609-613.
2. Glazener CMA and Cooper K. Anterior vaginal repair for urinary incontinence in women.Cochrane Database Syst Rev 2001, Issue 1.3. Burch J. Urethrovaginal fixation to Cooper’s ligament for stress incontinence, cystocele, and
prolapse. Am J Obstet Gynecol 1961;81:281-290.
4. Lapitan MC, Cody DJ, and Grant AM. Open retropubic colposuspension for urinaryincontinence in women. Cochrane Database Syst Rev 2005, Issue 3.
5. Bidmead J, Toozs-Hobson P, Cardozo L, Robinson D, Bailey J. Randomised comparison ofBurch colposuspension versus anterior colporrhaphy for patients with stress urinary
incontinence (letter). BJOG 2001;108:128-129"6. Colombo M, Vitobello D, Proietti F and Milani R. Randomised comparison of Burch
colposuspension versus anterior colporrhaphy in women with stress urinary incontinence and
anterior vaginal wall prolapse. BJOG 2000; 107: 544-551.
7. Dean NM, Ellis G, Wilson PD, and Herbison GP. Laparoscopic colposuspension for urinary
incontinence in women. Cochrane Database Syst Rev 2006, Issue 3.8. Su TH, Wang KG, Hsu CY, Wei HJ, Hong BK. Prospective comparison of laparoscopic and
traditional colposuspensions in the treatment of genuine stress incontinence. Acta Obstet
Gynecol Scand 1997;76:576-582.
9. Dean NM, Herbison P, Ellis G, Wilson D. Laparoscopic colposuspension and tension-freevaginal tape: a systematic review. BJOG 2006;113:1345-1353.
10. Albo ME, et al and Urinary Incontinence Treatment Network. Burch colposuspension versusfascial sling to reduce urinary stress incontinence. NEJM 2007;356:2143-2155.
11. Bai SW, Jeon JD, Chung KA, Kim JY, Kim S, Park KH. The effectiveness of modified 6corner suspension in patients with paravaginal defect and stress urinary incontinence. Int
Urogyne J 2002;13:303-307.
12. Bezerra CA, Bruschini H, Cody DJ. Traditional suburethral sling operations for urinaryincontinence in women. Cochrane Database Syst Rev 2005, Issue 3.
13. Lucas M, Emery S, Alan W, Kathy W. Failure of porcine xenograft sling in a randomizedcontrol trial of three sling materials in surgery for stress incontinence. Joint meeting of
International Continence Society & International Urogynecological Association. Paris,
France, 2004.
14. Wadie BS, Edwan A, Nabeeh AM. Autologous fascial sling vs polypropylene tape at short-term follow up: a prospective randomized study. J Urol 2005;174: 990-993.
15. Ulmsten U, Henriksson L, Johnson P, Varhos G. An ambulatory surgical procedure underlocal anesthesia for the treatment of female urinary incontinence. Int Urogynecol J Pelvic
Floor Dysfunc 1996;7: 81-86.
16. Delorme E. Transobturator urethral suspension: mini-invasive procedure in the treatment ofstress urinary incontinence in women. Prog Urol 2001;11:1306-13.
17. De Leval J. Novel surgical technique for the treatment of female stress urinary incontinence:transobturator vaginal tape inside-out. Eur Urol 2003;44:724-730.
-
8/9/2019 CPG Urogynecology
36/71
18. Latthe PM, Foon R, Toozs-Hobson P. Transobturator and retropubic tape procedures in stressurinary incontinence: a systematic review and meta-analysis of effectiveness and
complications. BJOG 2007;114: 522-31.
19. Ogah J, Cody JD, Rogerson L. Minimally invasive synthetic suburethral sling operations forstress urinary incontinence in women. Cochrane Database Syst Rev 2009, Issue 4.
20. Keegan PE, Atiemo K, Cody JD, McClinton S, Pickard R. Periurethral injection therapy for
stress urinary incontinence in women. Cochrane Database Syst Rev 2007, Issue 3.21. NICE Guidance on Urinary Incontinence. National Collaborating Center for Women’s and
Children’s Health, 2006, National Institute for Health and Clinical Excellence, 2006b.
22. Smith ARB, Dmochowski R, Hilton P, Rovner E, Nilsson CG, Reid FM, Chang D. Surgeryfor urinary incontinence in women. In: Abrams P, Cardozo L, Khoury S, and Wein A (Eds)
Incontinence: WHO – ICUD International Consultation on Incontinence, 4th
edition, 2009.
-
8/9/2019 CPG Urogynecology
37/71
CONSERVATIVE MANAGEMENT OF PELVIC ORGAN
PROLAPSEMaria Teresa C. Luna, MD
I. VAGINAL PESSARY
A vaginal pessary is a removable device placed into the vagina. It is designed tosupport different sites of pelvic organ prolapse (POP). Available pessaries are
either made of silicone or latex rubber.
1. Pessaries can be fitted in most women with prolapse, regardless of
prolapse stage or site of predominant prolapse. (Level III, Grade A)
Summary of Evidence
Vaginal pessaries are the standard nonsurgical treatment for POP. A
vaginal pessary can be properly fitted in 78% of patients with approximately
50% of those properly fitted continuing to use a pessary a year later.1-3
Pessaries are most often used when the patient has a strong preference fornonsurgical management of POP or when the patient’s health status confers a
significant risk for surgical morbidity and mortality. 4
2. Clinicians should discuss the option of pessary use with all women who
have prolapse that warrants treatment based on symptoms. In particular,
pessary use should be considered before surgical intervention in women
with symptomatic prolapse. (Level III, Grade B)
Summary of Evidence
Patient factors that determine the type of pessary to be used are sexual
activity, site of POP and stage of POP. If the patient is fitted with the correct
pessary size, she is not aware of its presence when she wears it, she can void
readily, freely and completely and the pessary stays in place (while seated on atoilet bowl and during ambulation). If the patient is fitted with the correctpessary type, no site of defect protrudes when the pessary is in place.
Vaginal atrophy should be treated before and concomitant with pessary
initiation.Serious complications such as erosions to adjacent organs are rare with
proper use and usually result only after a long time of neglect.
Pessary complications are rare occurrences in medically compliant patients. The most common side effects of vaginal pessaries are vaginal
discharge and odor. Other complications include vaginal bleeding, pelvic/vulvar/vaginal discomfort/pain, pessary expulsion, urinary incontinence
(UI), and rectal pain, depending on the type of pessary. Rarely, vaginal pessaries can cause major urinary, rectal and genital complications including
fistula, fetal impaction, hydronephrosis and urosepsis.5
The vaginal pessary is removed nightly, washed with soap and water
and replaced the next morning. After initial pessary placement, the patient isadvised to come back for check-up after 1 week, during which time, the
-
8/9/2019 CPG Urogynecology
38/71
vagina is inspected for erosions, abrasions, ulcerations, granulation tissue
formation and infection. Scheduling of subsequent visits is individualized.6
Vaginal estrogen is generally recommended to patients who, at the
time of their initial fitting or at subsequent follow up, are noted to have
vaginal atrophy or areas of ulceration or abrasions from pessary use. 7
3. Currently there is no evidence from randomized controlled trials (RCT)
upon which to base treatment of women with POP through the use of
mechanical devices/pessaries.8 There is no consensus on the use of
different types of device, the indications, nor the pattern of replacement
and follow-up care. (Level III, Grade B)
II. PELVIC FLOOR MUSCLE EXERCISE
Despite of the lack of high quality scientific evidence supporting pelvic
floor muscle exercise for prevention and treatment of POP, it poses norisk and cost to the patient. It is offered to all patients who are
asymptomatic or mildly symptomatic and are interested in preventing the
progression of the condition and who decline other treatments. There is
some encouragement from a feasibility study that pelvic floor muscle
training (PFMT), delivered by a physiotherapist to symptomatic women
in an outpatient setting, may reduce severity of prolapse.10
(Level II-3,
Grade B)
Summary of Evidence
The muscles of the pelvic floor help support the abdominal and pelvic
contents from below, help control bowel and bladder function and play a role
in sexual response.
Pelvic floor muscle exercise helps in reducing the progression of POP.
The pelvic floor muscle exercise, also known as the Kegel exercise,
has been thought to offer a number of benefits to the patient. Firstly, the
patient learns to consciously contract before and during increases in
abdominal pressure. Secondly, the pelvic floor muscle exercise builds permanent muscle volume and structure support.9
III. PATIENT EDUCATION AND LIFESTYLE MODIFICATION
Patients with POP should be counseled on the importance of various
lifestyle modifications that may prevent or improve their symptoms of
prolapse. (Level III, Grade C)
Summary of Evidence
Maintaining an ideal body weight limits the pressure that the
abdominal content places on the pelvic floor. Any activity that engages the
pelvic floor such as walking or gardening can help strengthen the muscles.Patients should be instructed to contract their pelvic floor muscles when lifting
-
8/9/2019 CPG Urogynecology
39/71
or straining. Patient education should also include bowel movement retraining.
This will teach a passing motion without straining the pelvic floor muscles.
Advising women on correct posture will in aid in preventing strain on the
pelvic floor muscles.11
References
1. Wu V, Farrel SA, Baskett TF, Flowerdew G. A simplified protocol for pessary management.Obstet Gynecol 1997;90:990-994.
2. Sulak PJ, Kuehl TJ, Shull BL. Vaginal pessaries and their use in pelvic relaxation. J Reprod Med 1993;38:919-923.
3. Clemons JL, et al. Patient satisfaction and changes in prolapse and urinary symptoms inwomen who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet
Gynecol 2004; 190(4): 1025–1029.
4. Rodriguez E, Trowbridge MD and Fenner DE. Conservative management of pelvic organ prolapse. Clin Obstet Gynecol 2005;48(3):668-681.
5. Jelovsek JE, Maher C, Barber MD. Pelvic organ prolapse. Lancet 2007;369:1027-1038.6. Farrell SA. Practice advice for ring pessary fitting and management. J SOGC 1997;19:625.
7. Poma PA. Management of incarcerated vaginal pessaries. J Am Geriatr Soc 1981;29:325-327.8. Hagen S, Stark D, et al. Conservative management of pelvic organ prolapse in women.
Cochrane Database Syst Rev 2006, Issue 4.
9. Bo K. Pelvic floor muscle training is effective in treatment of stress urinary incontinence, buthow does it work? Int Urogynecol J 2004;15:76.
10. Hagen S, Stark D, Maher C, et al. Conservative management of pelvic organ prolapse inwomen. Cochrane Database Syst Rev 2:CD003882, 2004.
11. Rodriguez E, Trowbridge MD, Fenner DE. Conservative management of pelvic organ prolapse. Clin Obstet Gynecol 2005;48(3):668-681.
-
8/9/2019 CPG Urogynecology
40/71
SURGICAL MANAGEMENT OF PELVIC ORGAN PROLAPSEManuel S. Ocampo Jr., MD and Lisa T. Prodigalidad-Jabson, MD
Previous to the latter half of the twentieth century, the concept of prolapse
surgery was based on fascial weakness and defects and so procedures were done toattenuate or strengthen ligaments or fascia supporting the pelvic organs. The work of
anatomists in the 1970’s resulted in discovering “breaks in the continuity of support
within the endopelvic fascia”. This thinking redirected how pelvic reconstructive
surgery is currently performed. This fulfilled the first goal of pelvic organ prolapse
(POP) repair that is to “restore normal anatomy”.1 In 2005, The Surgery for Pelvic
Organ Prolapse Committee of the World Health Organization (WHO)’s 3rd
International Consultation on Incontinence (ICI) made a comprehensive review of
POP surgery studies and published its recommendations based on the strength of
evidence using t